Close Menu

NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals announced this week that it has completed enrollment in a Phase II trial of its subcutaneously administered TTR-mediated amyloidosis (ATTR) drug revusiran, formerly known as ALN-TTRsc.

ATTR is a condition characterized by the accumulation of amyloid deposits in tissues due to mutations in the TTR gene. Revusarin, like its intravenously administered Phase III counterpart patisiran, is designed to silence both mutant and wild-type TTR.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Genetic genealogy has helped exonerate a man who has been jailed for 20 years, Agence France Presse reports.

NPR reports that many USDA researchers working at the two agencies that are relocating to the Kansas City area are declining to go.

A new report says genetically modified food might be necessary to be able to feed a planet of nearly 10 billion people, Bloomberg says.

In Nature this week: new RNA editing approach called LEAPER, draft assembly of Musa balbisiana banana genome, and more.

Aug
28
Sponsored by
Horizon Discovery

This webinar will provide an overview of alternatives to the popular Cas9 nuclease used in CRISPR gene editing.